-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on ResMed, Raises Price Target to $288

Benzinga·10/30/2026 17:08:58
Listen to the news
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $262 to $288.